Navigation Links
SynergEyes, Inc. Expands Launch of New Hybrid Contact Lens Design for Keratoconus Patients

CARLSBAD, Calif., Sept. 4 /PRNewswire/ -- SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, recently introduced a new advanced lens design for keratoconus patients. ClearKone(TM) is a revolutionary contact lens that takes advantage of the best features of the hybrid platform, providing superior visual acuity, centration, stability, and all-day comfort. The patent-pending design is optimized to vault the predominant irregularities of the keratoconic cornea, thus effectively restoring vision to a vast majority of irregular cornea patients, without compromising comfort or eye health, even in the most challenging cases. ClearKone(TM) is now available in the United States, Canada and Puerto Rico.

SynergEyes lenses are the only FDA-cleared hybrid contact lenses specifically designed for keratoconus vision correction. The SynergEyes(R) KC lens was introduced in 2006, and many keratoconus patients are successfully wearing this design. However, SynergEyes(R) KC is most successful on central, nipple cones, which represent only a portion of the total number of keratoconus cases.

"SynergEyes recognized the need to develop a hybrid contact lens design that could fit a much broader spectrum of keratoconus patients, including oval cones, highly advanced central cones, decentered cones and depending on the specifics of the case, globus keratoconus and pellucid marginal degeneration," says Kellie Kaseburg, Vice President of Global Marketing for SynergEyes. "The ClearKone(TM) lens does just that and will allow many more keratoconus patients to experience the benefits of hybrid technology."

The ClearKone(TM) lens utilizes revolutionary hybrid technology to give keratoconus patients the very best technology has to offer - the excellent visual clarity of a high-oxygen rigid gas permeable contact lens and the all-day comfort and convenience of a soft lens. What makes the ClearKone(TM) lens different from other SynergEyes lenses is the design of the lens itself and the technique used to fit it.

"The ClearKone(TM) hybrid contact lens gives keratoconus patients wearing RGP lenses or a piggyback system a new way to have clearer, more stable vision and better comfort," says Dr. Morris Sheffer of Charlotte, North Carolina. "The design of ClearKone(TM) enables the lens to center very well on irregularly shaped corneas, to provide crisper vision than any other contact lens we have tried. Since the lens is designed to 'vault' over the peak of the cornea, the comfort is also greatly improved. Our patients love the improvement in comfort and vision they get with ClearKone(TM)!"

ClearKone(TM) is currently being prescribed in a number of locations in the United States, Canada and Puerto Rico. Keratoconus patients can visit to locate a ClearKone(TM) practitioner.

Incorporating patented HyperBond(TM) technology and HydrolEyes(TM) surface science, the SynergEyes(R) contact lenses with FDA market clearance include: SynergEyes(R) A for naturally occurring ametropia, targeting patients with astigmatism, current gas permeable lens wearers, and patients demanding optimized vision; the SynergEyes(R) Multifocal lens for presbyopia; SynergEyes(R) KC and ClearKone(TM) for keratoconus; and the SynergEyes(R) PS for post-surgery and post-trauma refractive errors.


    Kellie Kaseburg
    Vice President, Global Marketing

This release was issued through eReleases(TM). For more information, visit

SOURCE SynergEyes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients
2. Misonix Restructures and Expands Sales Organization in Europe
3. United Concordia Dental Expands Benefit Options
4. Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
5. Transcend Medical Expands Leadership Team Appointing Chief Medical Officer and Vice President of Clinical Affairs
6. Health Robotics Expands CytoCare(TM) Global Presence With National Taiwan University Hospital and Pinnaclemed
7. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
8. Moszkito(R) Expands its Archy(TM) Footwear Collection to Include Closed-Toed Shoes for Fall 2009
9. Health Media Network Expands to New Markets
10. CareTech Expands Services to Garden City Hospital With Radiology Workflow Technology
11. Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial
Post Your Comments:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: